ICH-GCP
Also known as: Good Clinical Practice
International Council for Harmonisation guidelines for the design, conduct, and reporting of clinical trials involving human subjects.
ICH-GCP (International Council for Harmonisation — Good Clinical Practice) is the international ethical and scientific quality standard for the design, conduct, recording, and reporting of clinical trials involving human subjects, articulated principally in the ICH E6 Guideline first finalized in 1996, revised as E6(R2) in 2016 and as E6(R3) in 2023, with ongoing implementation. The framework establishes responsibilities for sponsors, investigators, and institutional review boards/independent ethics committees, requirements for protocol development and informed consent, standards for clinical trial monitoring and data integrity, adverse-event reporting requirements, and documentation expectations. ICH-GCP is the operational quality standard implemented by regulatory authorities including the US Food and Drug Administration, European Medicines Agency, Japan's Pharmaceuticals and Medical Devices Agency, and authorities in subsequent ICH-member jurisdictions, providing the framework within which pharmaceutical and medical-device clinical research is conducted globally and serving as common reference for trial-conduct standards across jurisdictions.
Core components
- Ethical foundations: thirteen ICH-GCP principles including informed consent, IRB/IEC approval, qualified investigators, scientifically sound protocols, foreseeable-risk versus anticipated-benefit consideration, subject privacy and confidentiality, conformance to GMP for investigational products
- Sponsor responsibilities: protocol development and amendments, investigator selection and oversight, monitoring (traditional and risk-based), safety reporting, data management, quality systems, regulatory submissions
- Investigator responsibilities: qualified medical care, adequate resources, communications with IRB/IEC, informed-consent process, protocol compliance, investigational-product accountability, safety reporting, records maintenance
- IRB/IEC requirements: composition, procedures, documentation, ongoing review, expedited and full-board review pathways
- Informed consent: comprehensive disclosure of trial purpose, procedures, risks, benefits, alternatives, voluntariness, right to withdraw, contact information, with documented written consent prior to enrollment
- Protocol development: scientific rationale, hypotheses and objectives, study design including statistical considerations, eligibility criteria, treatment plans, safety monitoring, ethics considerations
- Investigational product management: labeling, accountability, storage, dispensing, recall procedures
- Trial monitoring: source-data verification, protocol adherence, adverse-event identification, with R2 introducing risk-based monitoring as alternative to comprehensive source-data verification
- Adverse event reporting: serious adverse events (SAEs) and suspected unexpected serious adverse reactions (SUSARs) with defined reporting timelines to sponsor, IRB/IEC, and regulatory authorities
- Data integrity: ALCOA principles (attributable, legible, contemporaneous, original, accurate), with ALCOA+ (complete, consistent, enduring, available) for electronic systems
- Essential documents: trial master file (TMF) contents, retention periods, accessibility for inspection
- Quality systems: R2 introduced systematic quality-management requirements, R3 expanded these into fitness-for-purpose-oriented framework
- R3 restructuring: 2023 revision emphasizes principles-based approach over previous prescriptive structure, with greater attention to decentralized trials, real-world data, electronic records and signatures, sponsor-investigator-vendor relationships including emerging Clinical Research Organizations (CROs)
Primary use case
Foundational regulatory-quality framework for clinical-trial conduct globally; applied principally in: pharmaceutical drug development (Phase I-IV clinical trials for new drug applications and biological-license applications), medical-device clinical investigations, vaccine development trials, generic-drug bioequivalence studies, academic clinical research that anticipates regulatory submission, clinical-research-organization (CRO) operations, sponsor pharmacovigilance and safety surveillance, regulatory inspection programs (FDA Bioresearch Monitoring, EMA inspections, equivalent programs in ICH-member countries), institutional review board operations and accreditation; standard reference in clinical-research curricula, pharmaceutical-industry training, and regulatory-affairs certification.
Common criticisms
- ICH-GCP has substantial regulatory authority but specific critiques exist — critics including academic clinical-trial methodologists Richard Lehman and Iain Chalmers have argued that ICH-GCP's compliance-focused structure has produced documentation overhead and operational complexity that limits clinical research particularly for academic and investigator-initiated trials, with smaller research groups facing disproportionate compliance burden relative to their resources
- the framework has been argued to optimize for pharmaceutical-industry-sponsored trials in ways that fit awkwardly with academic, public-health, and developing-country research contexts where resource constraints and study questions differ substantially
- the historical period 1996-2016 of relatively prescriptive guidance has been argued to have produced 'box-ticking' compliance that did not always correspond to actual trial quality or subject protection, with E6(R2) and E6(R3) revisions explicitly attempting to address this through risk-based and fitness-for-purpose approaches
- informed-consent documents have been argued to grow excessively long and legalistic over time, paradoxically reducing rather than enhancing subject comprehension — the framework's response to this through E6(R3) is incompletely implemented
- cross-cultural applicability of the framework's specific informed-consent and confidentiality structures has been argued to fit certain Western institutional contexts more readily than others, with adaptation for developing-country and indigenous-population research raising substantive bioethics issues that the framework addresses only partially
- the relationship between ICH-GCP and the underlying ethical foundations (Nuremberg, Helsinki, Belmont) has been critiqued for sometimes prioritizing procedural compliance over substantive ethical evaluation — Helsinki principles like post-trial access to beneficial treatments are less operationally codified in ICH-GCP than the more procedural elements
- commercial-CRO consolidation in clinical-trial conduct has produced critique that ICH-GCP's sponsor-responsibility structure has not kept pace with the actual operational reality of multi-party sponsor-CRO-vendor-investigator relationships, with vendor management gaps emerging in inspection findings
- decentralized clinical trials (using digital health technologies, home-based assessments, remote consent) have evolved faster than the GCP framework's accommodation of them, with E6(R3) attempting to address this through technology-neutral principles
- the trend toward platform trials, master protocols, and adaptive designs has tested the framework's adaptability with mixed results
- criticism from outside the pharmaceutical-industry context (academic research, low-and-middle-income country research) has produced calls for tiered GCP frameworks that the ICH process has been slow to develop.